Tigecycline-Associated Coagulopathy: A Single-Center Retrospective Analysis

Abstract

<b><i>Introduction:</i></b> The purpose of this study was to assess clinical characteristics and risk factors for tigecycline-associated prothrombin time (PT) and activated partial thromboplastin time (aPTT) prolongation. <b><i>Methods:</i></b> We performed a retrospective analysis on coagulation parameters before and during tigecycline treatment in 55 patients in our hospital with severe infections, mainly pneumonia caused by <i>Acinetobacter baumannii</i>. Patients were divided into different groups according to prolongation of PT and aPTT, and clinical features involved were explored. Univariate and multivariable binary logistic regression analyses were used to identify risk factors for tigecycline-associated PT and aPTT increase. <b><i>Results:</i></b> We found that PT values increased from 12.73 ± 1.87 to 13.86 ± 2.06 during the treatment compared with premedication (<i>p</i> &#x3c; 0.001), and the aPTT level prolonged significantly from 33.63 ± 11.24 to 38.15 ± 11.81 (<i>p</i> &#x3c; 0.001). The multivariate analyses identified 2 variables that were associated with tigecycline-induced PT prolongation: albumin level (<i>p</i> = 0.018) and weight-adjusted tigecycline dosage (<i>p</i> = 0.005). In addition, treatment duration was the only risk factor for tigecycline-induced aPTT prolongation (<i>p</i> = 0.043). <b><i>Conclusion:</i></b> Albumin level, weight-adjusted tigecycline dosage, treatment duration may serve as risk indicators for tigecycline-associated coagulation dysfunction. Physicians should be careful with coagulation disorder when prescribing tigecycline in clinical practice, especially in patients with risk factors.